Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13

Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov (2011) 1.45

Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol (2010) 1.04

Palladium-catalyzed three-component diaryl sulfone synthesis exploiting the sulfur dioxide surrogate DABSO. Angew Chem Int Ed Engl (2013) 0.91

Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol (2008) 0.90

Hormonal therapy for prostate cancer. Rev Urol (2006) 0.85

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol (2008) 0.81

Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol (2006) 0.81

Molecular targets for radiation oncology in prostate cancer. Front Oncol (2011) 0.78

Controversies in the management of advanced prostate cancer. Br J Cancer (1999) 0.76

What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care? J Cancer Res Clin Oncol (2006) 0.76

Bicalutamide versus flutamide in combination therapy. Urology (1999) 0.75

Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol (2000) 4.28

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology (1995) 2.83

Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol (1995) 2.80

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66

A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol (1998) 2.32

Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet (1990) 2.31

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 2.18

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA (1991) 2.12

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07

Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet (1981) 2.06

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol (1998) 2.03

Data interpretation and integration of new tests into clinical practice. J Urol (1997) 2.00

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol (1997) 1.99

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93

Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol (1998) 1.88

Small cell carcinoma of the bladder and prostate. Urology (1995) 1.81

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol (1999) 1.81

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol (2001) 1.81

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72

Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol (1995) 1.71

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71

Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem (2001) 1.58

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology (1998) 1.57

De novo muscle invasive bladder cancer: is there a change in trend? J Urol (2001) 1.54

Sampling of radical prostatectomy specimens. How much is adequate? Am J Clin Pathol (1994) 1.51

Spontaneous retroperitoneal hemorrhage from a giant adrenal myelolipoma. J Urol (1996) 1.49

Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst (2001) 1.47

Transitional cell carcinoma of the prostate. J Urol (1991) 1.47

Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med (1981) 1.47

Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology (1999) 1.44

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer (1992) 1.44

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer (1993) 1.44

Prospective clinical trial of a human tumor cloning system. Cancer Res (1983) 1.44

Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst (1988) 1.41

Malignant melanoma of the female urethra: report of a case with 5-year survival and review of the literature. J Urol (1971) 1.40

Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases. J Urol (1994) 1.39

Does pericapsular lignocaine reduce pain during transrectal ultrasonography-guided biopsy of the prostate? BJU Int (2003) 1.38

Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res (1983) 1.38

Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol (1995) 1.36

Cardiac metastases from soft-tissue sarcomas. J Clin Oncol (1986) 1.36

The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. J Urol (1992) 1.36

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35

Patients' choice of treatment in stage D prostate cancer. Urology (1989) 1.34

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer (1995) 1.34

Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer (1985) 1.31

Renal pelvic cancer: a review of 611 patients treated in Illinois 1975-1985. Cancer Incidence and End Results Committee. Urology (1992) 1.30

Rapid eye movement sleep behavior disorder. A treatable parasomnia affecting older adults. JAMA (1987) 1.30

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol (2000) 1.28

Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res (1997) 1.28

Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol (2010) 1.27

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol (2000) 1.26

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer (1998) 1.25

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 1.23

Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol (2000) 1.22

Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 1.21

Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol (1980) 1.21

Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer (1984) 1.21

Renal cell carcinoma metastatic to the gallbladder or prostate: two case reports. Urology (1995) 1.20

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev (1999) 1.20

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19

Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol (1999) 1.18

Involvement of the genitourinary system in multiple primary malignant neoplasms: a review. J Clin Oncol (1983) 1.18

Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology (1996) 1.18

Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic strictures, and continence. Urology (1998) 1.17

Malignant mesothelioma. The University of Minnesota experience. Cancer (1984) 1.17

The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol (1997) 1.17

Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol (1987) 1.16

Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer (1980) 1.15

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15

Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res (1996) 1.14

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol (2005) 1.14

Complications of advanced prostate cancer. Urology (1999) 1.13

Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int (2003) 1.13

Risk factors for bladder tumors in spinal cord injury patients. J Urol (1996) 1.11

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol (1997) 1.11

One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol (1996) 1.10

Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J Urol (2001) 1.09

Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep (1980) 1.09

Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer (1991) 1.08

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol (1988) 1.08

Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol (1996) 1.07

Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res (1977) 1.07

Cautionary note on the use of dUMP-containing PCR primers with Pfu and VentR DNA polymerases. Biotechniques (1996) 1.06

Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol (1996) 1.06

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer (2001) 1.05

A review of chemotherapy trials for malignant mesothelioma. Chest (1998) 1.05